NCT04430283 - Evaluation of FDY-5301 in Major Trauma Patients in ICU | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 20, 2021

Primary Completion Date

March 4, 2022

Study Completion Date

March 4, 2022

Conditions

ICU Acquired Weakness

Interventions

DRUG

FDY-5301

FDY-5301 is Sodium Iodide administered as an isotonic solution for intravenous injection with a concentration of 7.2 mg/ml.

OTHER

Placebo

Placebo is delivered as a single dose, non-reserved liquid parenteral consisting of a formulation matched compendial saline.

Trial Locations (5)

University of Florida Health Shands Hospital, Gainesville

The Ohio State University Wexner Medical Center, Columbus

Harbor-UCLA Medical Center, Torrance

Harborview, Seattle

Massachusetts General Hospital, Harvard Medical School, Boston